

Econ Healthcare (Asia) Limited and its subsidiaries Registration Number: 200400965N

Condensed consolidated financial statements For the six months and full year ended 31 March 2024

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("Exchange"). This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View #06-07, Marina One West Tower, Singapore 018937.

Table of contents	Page
Condensed consolidated income statement	2
Condensed consolidated statement of comprehensive income	4
Condensed consolidated statements of financial position	5
Condensed consolidated statements of changes in equity	7
Condensed consolidated statement of cash flows	10
Notes to the condensed consolidated financial statements	12
Other information required for Full Year Announcement	38

Certain numerical figures set out in this Announcement, including financial data presented in millions or thousands and percentages, have been subject to rounding adjustments, and, as a result, the totals of the data in this Announcement may vary slightly from the actual arithmetic totals of such information. Percentages and amounts reflecting changes over time periods relating to financial and other data set forth in paragraph 4 of the section in this Announcement entitled "Other Information required for Full Year Announcement" are approximate figures and have been calculated using the numerical data in the Group's consolidated financial statements or the tabular presentation of other data (subject to rounding) contained in this Announcement, as applicable, and not using the numerical data in the narrative description thereof.

Condensed consolidated income statement
For the six months and full year ended 31 March 2024

			ths ended Iarch				
	Note	2024 S\$'000	2023* S\$'000 (Re- presented)	Change %	2024 S\$'000	2023* S\$'000 (Re- presented)	Change %
Continuing operations			presenteu)			presenteu)	
Revenue	5	26,287	22,017	19.4	50,786	43,012	18.1
Other income	6	4,630	5,477	(15.5)	6,974	8,698	(19.8)
Supplies and consumables		(3,426)	(3,122)	9.7	(6,686)	(6,055)	10.4
Staff costs		(14,096)	(11,839)	19.1	(27,697)	(23,039)	20.2
Depreciation of property, plan and equipment	nt	(722)	(654)	10.4	(1,361)	(1,239)	9.8
Depreciation of right-of-use		(2, 740)	(27(7))	(0, 5)	(7, 471)	(7, 40, 4)	(0,2)
assets		(3,748) (712)	(3,767) (714)	(0.5) (0.3)	(7,471) (1,541)	(7,494) (1,466)	(0.3) 5.1
Utilities expenses Impairment losses/(reversal) of	n	(712)	(714)	(0.5)	(1,341)	(1,400)	3.1
trade receivables	Л	(30)	28	N.M.	(26)	35	N.M.
Fair value (losses)/gains on investment in quoted		(50)	20	11.111.	(20)	55	10.101.
securities		(50)	61	N.M.	(73)	59	N.M.
Gains on disposal of investment in quoted							
securities, net		-	-	N.M.	27	-	N.M.
Other operating expenses	-	(3,153)	(2,085)	51.2	(5,355)	(4,351)	23.1
		4,980	5,402	(7.8)	7,577	8,160	(7.1)
Finance costs, net	7	(579)	(383)	51.2	(994)	(943)	5.4
Profit before tax from				(1 - -)			(2.2)
continuing operations	8	4,401	5,019	(12.3)	6,583	7,217	(8.8)
Tax credit/(expense)	9	95	(1,088)	N.M.	(249)	(1,468)	(83.0)
Profit for the period/year from continuing operations, net of tax		4,496	3,931	14.4	6,334	5,749	10.2
Discontinued operations Profit/(loss) from discontinue	d						
operations, net of tax		558	(1,344)	N.M.	290	(1,587)	N.M.
Profit for the period/year		5,054	2,587	95.4	6,624	4,162	59.2

N.M. – Not meaningful

*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

Condensed	consolidated income statement
East the star	months and full mean and ad 21 Manah

		Six mont 31 M					
	Note	2024 S\$'000	2023* S\$'000 (Re- presented)	Change %	2024 S\$'000	2023* S\$'000 (Re- presented)	Change %
Profit/(loss) attributable to:			•			• /	
Owner of the Company							
Profit from continuing							
operations, net of tax		4,431	3,983	11.2	6,298	5,832	8.0
Profit/(loss) from discontinued			(0.0.0)		10.1	(0.0.0)	
operations, net of tax	-	312	(822)	N.M.	124	(983)	N.M.
Profit for the period/year							
attributable to owner of the Company		4,743	3,161	50.0	6,422	4,849	32.4
Company	-	4,743	5,101		0,422	4,049	
Non-controlling interests							
Profit/(loss) from continuing							
operations, net of tax		66	(74)	N.M.	39	(112)	N.M.
Profit/(loss) from discontinued							
operations, net of tax	_	246	(500)	N.M.	163	(575)	N.M.
Profit/(loss) for the period/year							
attributable to non-							
controlling interests	-	311	(574)	N.M.	202	(687)	N.M.
Profit for the period/year	=	5,054	2,587	95.3	6,624	4,162	59.2
Earnings per share for the period/year from continuing operations attributable to owner of the Company							
Basic and diluted earnings per							
share (cents)	17	1.72	1.55	10.7	2.44	2.27	7.7
Earnings per share for the period/year							
Basic and diluted earnings per share (cents)	17	1.84	1.23	49.3	2.49	1.89	32.1
share (cents)	· · / =	1.04	1.23	= +2.5	2.47	1.09	= 52.1

N.M. – Not meaningful

*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

	Six mont 31 M	larch		Full year 31 Ma		
	2024 S\$'000	2023* S\$'000 (Represented)	Change %	2024 S\$'000	2023* S\$'000 (Re- presented)	Change %
Profit for the period/year	5,054	2,587	95.4	6,624	4,162	59.2
Other comprehensive income Items that are or may be reclassified subsequently to profit or loss:						
Foreign currency translation differences – foreign operations	(104)	(583)	(82.2)	(779)	(1,212)	(12.5)
Total comprehensive income for the period/year	4,950	2,004	147.0	5,845	2,950	88.6
Total comprehensive income attributable to:						
Owner of the Company	4,465	2,676	66.9	5,635	3,681	53.1
Non-controlling interests	485	(672)	N.M.	210	(731)	N.M.
Total comprehensive income for the period/year	4,950	2,004	147.0	5,845	2,950	98.1
Attributable to owner of the Company:						
Total comprehensive income from continuing operations, net of tax Total comprehensive income from	4,029	3,498	15.2	5,387	4,664	15.5
discontinued operations, net of tax	436	(822)	N.M.	248	(983)	N.M.
Total comprehensive income for		\/_	-		`,	-
the period/year attributable to owner of the Company	4,465	2,676	66.9	5,635	3,681	53.1

Condensed consolidated statement of comprehensive income For the six months and full year ended 31 March 2024

N.M. – Not meaningful

*The comparative figures have been re-presented to report profit and loss items separately for continuing and discontinued operations.

AS at 51 Warch 2024		Gro	un	Com	Company			
	Note	31 March 2024 S\$'000	31 March 2023 S\$'000	31 March 2024 S\$'000	31 March 2023 S\$'000			
Assets								
Property, plant and								
equipment	10	16,578	18,328	744	724			
Right-of-use assets	11	35,051	39,746	2,749	2,127			
Investment property	12	7,177	7,554	_	_			
Intangible asset	22	5,110	-	_	_			
Subsidiaries		—	-	32,622	25,369			
Associate		—	21	-	—			
Deferred tax assets		364	108	225	_			
Trade and other receivables	13	2,302	1,736	3,275	2,892			
Non-current assets	_	66,582	67,493	39,615	31,112			
Inventories		3	10	_	_			
Current tax assets		62	101	_	_			
Trade and other receivables	13	10,376	6,291	4,474	3,118			
Investments in quoted securities		1,069	755	1,069	755			
Cash and short-term								
deposits		16,181	24,621	4,521	12,789			
	_	27,691	31,778	10,064	16,662			
Assets of disposal group classified as held for sale	21	11,100	_	_	_			
Current assets	21 _	38,791	31,778	10,064	16,662			
Total assets	-	105,373	99,271	49,679	47,774			
Liabilities								
Provision for restoration								
costs		733	639	83	218			
Deferred capital grants		2,600	3,197	-	- 210			
Deferred tax liabilities		2,000	426	_	4			
Lease liabilities		29,652	35,542	1,996	1,024			
Loans and borrowings	18	1,242	1,798	-				
Non-current liabilities		34,250	41,602	2,079	1,246			
Current tax liabilities		1,101	1,172	_	120			
Lease liabilities		7,003	6,770	467	1,221			
Loans and borrowings	18	2,382	3,285					
Trade and other payables	19	7,154	7,916	2,020	2,429			
Trade and other payables	19	17,640	19,143	2,020	3,770			
Liabilities directly associated with disposal group classified as held								
for sale	21	8,995	_	_	_			
Current liabilities		26,635	19,143	2,487	3,770			
Total liabilities	_	60,885	60,745	4,566	5,016			
- our nuonnuos	-	00,005	00,745	ч,500	5,010			

Condensed consolidated statements of financial position As at 31 March 2024

		Gro	up	Company		
	Note	31 March 2024 S\$'000	31 March 2023 S\$'000	31 March 2024 S\$'000	31 March 2023 S\$'000	
Share capital	14	29,983	28,255	29,983	28,255	
Currency translation reserve	15	(4,704)	(4,091)	-	-	
Merger reserve	15	(99)	(99)	-	-	
Reserves of disposal group						
classified as held for sale	21	(174)	_	-	-	
Accumulated profits		19,394	14,694	15,130	14,503	
Equity attributable to						
owner of the Company		44,400	38,759	45,113	42,758	
Non-controlling interests		88	(233)	—	-	
Total equity		44,488	38,526	45,113	42,758	
Total equity and liabilities		105,373	99,271	49,679	47,774	

Condensed consolidated statements of financial position As at 31 March 2024

Condensed consolidated statement of changes in equity For the full year ended 31 March 2024

Group	Note	Share capital S\$'000	Currency translation reserve S\$'000	Merger reserve S\$'000	Reserves of disposal group classified as held for sale S\$'000	Accumulated profits S\$'000	Total equity attributable to owner of the Company S\$'000	Non- controlling interests S\$'000	Total equity S\$'000
As at 1 April 2023		28,255	(4,091)	(99)	_	14,694	38,759	(233)	38,526
Total comprehensive income for the year Profit for the year Other comprehensive income		_	_		_	6,422	6,422	202	6,624
Foreign currency translation differences – foreign operations		_	(787)	_	_	_	(787)	8	(779)
Total comprehensive income for the year	-		(787)			6,422	5,635	210	5,845
<i>Transactions with owner,</i> <i>recognised directly in equity</i> Dividends paid		_	_	_	_	(1,722)) (1,722)	_	(1,722)
Shares issued	14	1,728	_	-	-	(1,122)	1,728	_	1,728
Capital contribution by non- controlling interests		_	_	_	_	_	_	111	111
Reclassification to reserves of disposal group classified as held for sale			174	_	(174)	_			_
Total contributions by and distribution to owner	-	1,728	174	_	(174)	(1,722)) 6	111	117
As at 31 March 2024	-	29,983	(4,704)	(99)	· · · · ·			88	44,488

Condensed consolidated statement of changes in equity For the full year ended 31 March 2024

Group	Share capital S\$'000	Currency translation reserve S\$'000	Merger reserve S\$'000	Accumulated profits S\$'000	Total equity attributable to owner of the Company S\$'000	Non-controlling interests S\$'000	Total equity S\$'000
As at 1 April 2022	28,255	(2,923)	(99)	10,436	35,669	273	35,942
Total comprehensive income for the year Profit/(loss) for the year <i>Other comprehensive income</i>	_	_	_	4,849	4,849	(687)	4,162
Foreign currency translation differences – foreign operations	_	(1,168)	_	_	(1,168)	(44)	(1,212)
Total comprehensive income for the year		(1,168)		4,849	3,681	(731)	2,950
<i>Transactions with owner, recognised</i> <i>directly in equity</i> Dividends paid Capital contribution by non-	_	_	_	(591)	(591)	_	(591)
controlling interests		_	-	-	_	225	225
Total contributions by and distribution to owner	_	_	_	(591)	(591)	225	(366)
As at 31 March 2023	28,255	(4,091)	(99)	14,694	38,759	(233)	38,526

Condensed statements of changes in equity For the full year ended 31 March 2024

Company	Note	Share capital S\$'000	Retained earnings S\$'000	Total equity S\$'000
As at 1 April 2023		28,255	14,503	42,758
Profit for the year, representing total comprehensive income for the year		_	2,349	2,349
Transactions with owner, recognised directly in equity				
Dividends paid		_	(1,722)	(1,722)
Shares issued	14	1,728	_	1,728
Total transactions with owners	_	1,728	(1,722)	6
As at 31 March 2024	-	29,983	15,130	45,113
As at 1 April 2022		28,255	9,891	38,146
Profit for the year, representing total comprehensive income for the year		_	5,203	5,203
Transactions with owner, recognised directly in equity				
Dividends paid		_	(591)	(591)
Total transactions with owners	-	_	(591)	(591)
As at 31 March 2023	=	28,255	14,503	42,758

Condensed consolidated statement of cash flows For the full year ended 31 March 2024

	2024 S\$'000	2023 S\$'000
Cash flows from operating activities		
Profit before tax from continuing operations	6,583	7,217
Profit/(loss) before tax from discontinued operations	309	(1,587)
	6,892	5,630
Adjustments for:		
Amortisation of deferred capital grant	(586)	(321)
Write-off of property, plant and equipment	14	67
Depreciation of property, plant and equipment	1,530	1,477
Depreciation of right-of-use assets	7,638	7,872
Gain on termination of leases	(1)	_*
Gain on disposal of motor vehicle	(201)	_
Impairment losses/(reversal) on trade receivables	26	(35)
(Reversal of)/impairment losses on property, plant and		
equipment	(232)	568
Impairment losses on right-of-use assets	47	380
Interest income	(308)	(214)
Interest expense	1,609	1,512
Unwinding of discount on provisions	10	7
Share of (profit)/loss of associate, net of tax	(3)	30
Dividends income from investment in quoted securities	(49)	_
Fair value losses/(gains) on investment in quoted securities	73	(59)
Gain on disposal of investment in quoted securities, net	(27)	
	16,432	16,914
Changes in:		
- Trade and other receivables	(2,668)	(715)
- Trade and other payables	132	(3,428)
- Inventories	7	4
Cash generated from operations	13,903	12,775
Tax paid	(1,243)	(1,044)
Net cash from operating activities	12,660	11,731
Cash flows from investing activities		
Finance lease received	_	18
Interest received	297	169
Purchase of property, plant and equipment	(1,785)	(3,631)
Capital grants received	787	1,980
Dividends income from investment in quoted securities	49	_
Investments in quoted securities	(2,266)	(696)
Proceeds from disposal of quoted securities	1,905	_
Acquisition of subsidiary, net of cash acquired	(6,828)	_
Net cash used in investing activities	(7,841)	(2,160)
-		· · · · ·

* Less than S\$1,000

Condensed consolidated statement of cash flows For the full year ended 31 March 2024

	2024 S\$'000	2023 S\$'000
Cash flows from financing activities		
Capital contribution by non-controlling interests	111	225
Repayment of borrowings	(1,252)	(1,733)
Payment of principal portion of lease liabilities	(7,415)	(7,583)
Interest paid	(1,612)	(1,513)
Dividends paid	(1,722)	(591)
Net cash used in financing activities	(11,890)	(11,195)
Net decrease in cash and cash equivalents	(7,071)	(1,624)
Cash and cash equivalents as at 1 April	24,557	26,035
Effect of exchange rate fluctuations on cash held	86	146
Cash and cash equivalents as at 31 March	17,572	24,557

For the purpose of the consolidated cash flow statement, cash and cash equivalents comprise the following at the end of the reporting period:

	2024 S\$'000	2023 S\$'000
Cash at bank and fixed deposits for continuing operations	16,181	24,621
Less: Fixed deposits with maturity more than 90 days at year		
end	(35)	(35)
Less: Restricted fixed deposit	(28)	(29)
Add: Cash at bank attributable to disposal group classified as		
held for sale	1,454	_
Cash and cash equivalents in consolidated statement of cash		
flows	17,572	24,557

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

1 Corporate information

Econ Healthcare (Asia) Limited (the "Company") is a limited liability company incorporated and domiciled in Singapore and is listed on the Catalist Board of Singapore Exchange Securities Trading Limited ("SGX-ST").

The registered office and principal place of business of the Company is located at 160 Changi Road, #05-01-13 Hexacube, Singapore 419728.

The immediate and ultimate holding companies are Econ Healthcare Pte. Ltd. and Econ Investment Holdings Pte. Ltd. respectively, both of which are incorporated in Singapore.

The principal activity of the Company is investment holding. The principal activities of the subsidiaries are those relating to the operation of medicare centres and nursing homes, provision of hospital extension ward management services, homecare services and ambulance services, emergency ambulance services and medical transport services, letting of properties and investment holding.

2 Basis of preparation

The condensed consolidated financial statements for the six months and full year ended 31 March 2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) ("SFRS(I)") 1-34 *Interim Financial Reporting* by the Accounting Standards Council Singapore. The condensed consolidated financial statements do not include all of the information required for a complete set of financial statements. However, selected explanatory notes are included to explain the events and transactions that are significant to understanding of the changes in the Group's financial position and performance since the last interim financial statements for the six-month period ended 30 September 2023.

The condensed consolidated financial statements are presented in Singapore dollar ("S\$") and all values are rounded to the nearest thousand ("S\$'000"), except when otherwise indicated.

2.1 New and amended standards adopted by the Group

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except in the current financial year, the Company has adopted all the new and revised standards which are effective for annual financial periods beginning on or after 1 April 2023. The adoption of these standards did not have any material effect on the financial performance or position of the Group.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

2.2 Use of judgements and estimates

In preparing the condensed consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2023.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the period under review.

4 Segment information

The Group has two (2) reportable segments, as described below, which are the Group's strategic business units. The strategic businesses are managed separately because they require different operation needs and marketing strategies. For each operating segment, the Group's Chief Executive Officer reviews the internal management reports on a monthly basis.

For the purpose of financial reporting, the following summary describes the operations in each of the Group's reportable segments:

•	Medicare centres and nursing homes	:	Include provision of residential nursing care services, home care services, physiotherapy and rehabilitation services, clinical services and TCM treatments in medicare centres and nursing homes.
•	Other operation and ancillary services	:	Include provision of management services, ambulance services, emergency ambulance services and medical transport services, course fees, the offering of TCM services at the Group's

TCM clinics and other ancillary services.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Information about reportable segments

Six months ended 31 March 2024 Revenue 25,262 341 1,025 (341) 26,287 Inter-segment revenue $ 4,956$ $ 4,956$ $ 4,956$ $ 4,956$ $(4,956)$ $ 25,262$ 341 $5,981$ $(5,297)$ $26,287$ Results: Segment results $4,885$ 733 (297) (291) $5,030$ Unallocated expenses: Fair (993) (156) 27 543 (579) Unallocated expenses: Fair $ (50)$ 522 $4,401$ Significant non-cash items Depreciation of property, plant and equipment for 563 $ 159$ $ 722$ Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 4863$ $(4,863)$ $-$ 2023 Revenue $21,587$ <th>5</th> <th>Medicare centres and nursing homes S\$'000</th> <th>Medicare centres and nursing homes (Discontinued operations) S\$'000</th> <th>Other operation and ancillary services S\$'000</th> <th>Eliminations and adjustments S\$'000</th> <th>Total S\$'000</th>	5	Medicare centres and nursing homes S\$'000	Medicare centres and nursing homes (Discontinued operations) S\$'000	Other operation and ancillary services S\$'000	Eliminations and adjustments S\$'000	Total S\$'000
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$						
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		25 262	241	1.025	(241)	76 797
Z Z <thz< th=""> Z <thz< th=""> <thz< th=""></thz<></thz<></thz<>		25,202	541	,	· · ·	20,287
Results: 4,885 733 (297) (291) 5,030 Net finance costs (993) (156) 27 543 (579) Unallocated expenses: Fair value losses on investment in $-$ - - (50) Segment profit before tax 3,892 577 (270) 252 4,401 Significant non-cash items $-$ - - - (50) Depreciation of property, plant and equipment 563 - 159 - 722 Depreciation of right-of-use assets 3,296 - 452 - 3,748 Impairment losses on trade receivables 30 - - - 30 Six months ended 31 March 2023 22 - - 3,748 Revenue 21,587 275 430 (275) 22,017 Inter-segment revenue 21,587 275 5,293 (5,138) 22,017 Results: Segment results 5,209 (1,179) (114) 1,425 5,341 <td>Inter-segment revenue</td> <td>25,262</td> <td>341</td> <td></td> <td></td> <td>26.287</td>	Inter-segment revenue	25,262	341			26.287
Segment results 4,885 733 (297) (291) 5,030 Net finance costs (993) (156) 27 543 (579) Unallocated expenses: Fair value losses on investment in $ -$ (50) Segment profit before tax 3,892 577 (270) 252 4,401 Significant non-cash items Depreciation of property, plant and equipment 563 $-$ 159 $-$ 722 Depreciation of right-of-use assets 3,296 $-$ 452 $-$ 3,748 Impairment losses on trade receivables 30 $ -$		- 7 -		- ,		- ,
Net finance costs (993) (156) 27 543 (579) Unallocated expenses: Fair value losses on investment in quoted securities $ -$ (50) Segment profit before tax $3,892$ 577 (270) 252 $4,401$ Significant non-cash items Depreciation of property, plant and equipment 563 $ 159$ $ 722$ Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 2023 $ 30$ Revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities <t< td=""><td></td><td>1 005</td><td>722</td><td>(207)</td><td>(201)</td><td>5 020</td></t<>		1 005	722	(207)	(201)	5 020
Unallocated expenses: Fair value losses on investment in quoted securities $-$ $ -$ $ -$ (50) Segment profit before tax $3,892$ 577 (270) 252 $4,401$ Significant non-cash items Depreciation of property, plant and equipment 563 $3,296$ $-$ 452 $-$ $ 722$ Depreciation of right-of-use assets $3,296$ 30 $-$ $ -$ $ 3,748$ Impairment losses on trade receivables 30 $ -$ $ -$ $ 30$ Six months ended 31 March 2023 Revenue $21,587$ 2.75 275 430 2.1587 $22,017$ Inter-segment revenue $21,587$ 2.75 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $1,425$ $5,341$ Net finance costs value gains on investment in quoted securities $-$ $-$ $ -$ $ -$ $-$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 97 (159) 654 Depreciation of property, plant and equipment Depreciation of property, plant and equipment assets $2,848$ 184 919 (184) $3,767$						
value losses on investment in quoted securities $ (50)$ Segment profit before tax $3,892$ 577 (270) 252 $4,401$ Significant non-cash items Depreciation of property, plant and equipment 563 $ 159$ $ 722$ Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 30 $ 30$ External revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ <		(993)	(150)	21	545	(379)
quoted securities $ (50)$ Segment profit before tax $3,892$ 577 (270) 252 $4,401$ Significant non-cash items Depreciation of property, plant and equipment 563 $ 159$ $ 722$ Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 203 $8evenue$ $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $21,587$ 275 $5,293$ $(5,138)$ $22,017$ Inter-segment revenue $21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs value gains on investment in quoted securities $ -$ Gegment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of property, plant ansets $2,848$ 184 919 (184) $3,767$	-					
Segment profit before tax $3,892$ 577 (270) 252 $4,401$ Significant non-cash items Depreciation of property, plant and equipment 563 $ 159$ $ 722$ Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 30 $ 30$ Revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$		_	_		_	(50)
$\begin{array}{c cccccccccccc} Depreciation of property, plant and equipment 563 - 159 - 722 \\ Depreciation of right-of-use assets 3,296 - 452 - 3,748 \\ Impairment losses on trade receivables 30 30 \\ \hline Six months ended 31 March 2023 \\ \hline Revenue \\ External revenue 21,587 275 430 (275) 22,017 \\ Inter-segment revenue 21,587 275 5,293 (5,138) 22,017 \\ \hline Inter-segment revenue 4,863 (4,863) - 21,587 275 5,293 (5,138) 22,017 \\ \hline Results: \\ Segment results 5,209 (1,179) (114) 1,425 5,341 \\ Net finance costs (1,917) (143) 140 1,537 (383) \\ Unallocated expenses: Fair value gains on investment in quoted securities 61 \\ Segment profit before tax 3,292 (1,322) 26 2,962 5,019 \\ \hline Significant non-cash items \\ Depreciation of right-of-use assets 2,848 184 919 (184) 3,767 \\ (Reversal of) impairment losses \\ \hline \end{array}$	-	3,892	577	(270)	252	
Depreciation of right-of-use assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 30 $ 30$ External revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $ 4.863$ (4.863) $-$ Inter-segment revenue $ 4.863$ (4.863) $-$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ 61$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 <td>Depreciation of property, plant</td> <td>563</td> <td>_</td> <td>159</td> <td>_</td> <td>722</td>	Depreciation of property, plant	563	_	159	_	722
assets $3,296$ $ 452$ $ 3,748$ Impairment losses on trade receivables 30 $ 30$ Six months ended 31 March 2023 30 $ 30$ Revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $ 4,863$ $(4,863)$ $ 21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$						
receivables 30 - - - 30 Six months ended 31 March 2023 Revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $ 4,863$ $(4,863)$ $ 21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results: Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$		3,296	_	452	_	3,748
2023RevenueExternal revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $ 4,863$ $(4,863)$ $ 21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$	-	30				30
External revenue $21,587$ 275 430 (275) $22,017$ Inter-segment revenue $ 4,863$ $(4,863)$ $ 21,587$ 275 $5,293$ $(5,138)$ $22,017$ Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$	2023					
Inter-segment revenue $ 4,863$ $(4,863)$ $-$ 21,5872755,293 $(5,138)$ 22,017Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ 61$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash itemsDepreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$						
21,587 275 $5,293$ $(5,138)$ $22,017$ Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$ (Reversal of) impairment losses $ -$		21,587	275		· · · ·	22,017
Results:Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ 61$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$ (Reversal of) impairment losses 2 2 8 184 919 (184) $3,767$	Inter-segment revenue		275			
Segment results $5,209$ $(1,179)$ (114) $1,425$ $5,341$ Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ 61$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$		21,387	213	5,295	(3,138)	22,017
Net finance costs $(1,917)$ (143) 140 $1,537$ (383) Unallocated expenses: Fair value gains on investment in quoted securities $ -$ Segment profit before tax $3,292$ $(1,322)$ 26 $2,962$ $5,019$ Significant non-cash items Depreciation of property, plant and equipment 557 159 97 (159) 654 Depreciation of right-of-use assets $2,848$ 184 919 (184) $3,767$	Results:					
Unallocated expenses: Fair value gains on investment in quoted securities61Segment profit before tax3,292(1,322)262,9625,019Significant non-cash itemsDepreciation of property, plant and equipment55715997(159)654Depreciation of right-of-use assets2,848184919(184)3,767(Reversal of) impairment losses	Segment results	5,209	(1,179)	· · ·		5,341
value gains on investment in quoted securities61Segment profit before tax3,292(1,322)262,9625,019Significant non-cash itemsDepreciation of property, plant and equipment55715997(159)654Depreciation of right-of-use assets2,848184919(184)3,767(Reversal of) impairment losses		(1,917)	(143)	140	1,537	(383)
Segment profit before tax3,292(1,322)262,9625,019Significant non-cash items Depreciation of property, plant and equipment55715997(159)654Depreciation of right-of-use assets2,848184919(184)3,767(Reversal of) impairment losses	value gains on investment in	_	_		_	61
Depreciation of property, plant and equipment55715997(159)654Depreciation of right-of-use assets2,848184919(184)3,767(Reversal of) impairment losses	-	3,292	(1,322)	26	2,962	5,019
Depreciation of right-of-use assets2,848184919(184)3,767(Reversal of) impairment losses						
assets 2,848 184 919 (184) 3,767 (Reversal of) impairment losses		557	159	97	(159)	654
	assets	2,848	184	919	(184)	3,767
		(28)	_		_	(28)

For the six months and full	year periou	Medicare	ITCH 2024		
Full year ended 31 March	Medicare centres and nursing homes S\$'000	centres and nursing homes (Discontinued operations) S\$'000	Other operation and ancillary services S\$'000	Eliminations and adjustments S\$'000	Total S\$'000
2024					
Revenue					
External revenue	49,316	665	,	(665)	50,786
Inter-segment revenue	40.216		9,967	(9,967)	50 796
	49,316	665	11,437	(10,632)	50,786
Results:					
Segment results	7,343	600		(343)	7,623
Net finance costs Unallocated expenses: Fair	(2,188)	(294)	123	1,365	(994)
value losses on investment in					
quoted securities	_	-		_	(73)
Unallocated expenses: Gains on					
disposal of investment in					
quoted securities				-	27
Segment profit before tax	5,155	306	5 146	1,022	6,583
Significant non-cash items Depreciation of property, plant and equipment Depreciation of right-of-use	1,111	169	250	(169)	1,361
assets	6,123	167	1,348	(167)	7,471
Impairment losses on trade	- 7 -		y		- 7 -
receivables	26			_	26
Full year ended 31 March 2023 Revenue					
External revenue	42,123	495	889	(495)	43,012
Inter-segment revenue	,	-	9,333	(9,333)	,
	42,123	495	10,222	(9,828)	43,012
Results:					
Segment results	7,666	(1,273)	188	1,520	8,101
Net finance costs	(2,465)	(284)		1,678	(943)
Unallocated expenses: Fair value gains on investment in quoted securities	_	_		_	59
Segment profit before tax	5,201	(1,557)	316	3,198	7,217
	,			,	·
Significant non-cash items Depreciation of property, plant and equipment	1,063	238	176	(238)	1,239
Depreciation of right-of-use assets	5,654	378	1,840	(378)	7,494
(Reversal of) impairment losses on trade receivables	(35)				(35)

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

	Medicare centres and nursing homes S\$'000	Other operation and ancillary services S\$'000	Eliminations S\$'000	Total S\$'000
As at 31 March 2024				
Assets:				
Segment assets	76,849	76,785	(59,787)	93,847
Tax assets	195	231	-	426
Assets of disposal group classified				
as held for sale	11,100	-	—	11,100
Total assets	88,144	77,016	(59,787)	105,373
Liabilities:	= ()= 2	24.405	(50.400)	
Segment liabilities	74,372	34,497	(58,103)	50,766
Tax liabilities	826	298	_	1,124
Liabilities directly associated with				
disposal group classified as held	9.005			8 00 <i>5</i>
for sale	8,995	24.705	(59.102)	8,995
Total liabilities	84,193	34,795	(58,103)	60,885
Capital expenditure	701	806		1,507
Capital expenditure to non-current	701	800	—	1,307
assets of disposal group classified				
as held for sale	300	_	_	300
Total capital expenditure	1,001	806		1,807
i otar capitar experientere	1,001	000		1,007
As at 31 March 2023				
Assets:				
Segment assets	85,057	69,256	(55,251)	99,062
Tax assets	209	_	_	209
Total assets	85,266	69,256	(55,251)	99,271
Liabilities:				
Segment liabilities	82,762	31,232	(54,847)	59,147
Tax liabilities	1,473	125	_	1,598
Total liabilities	84,235	31,357	(54,847)	60,745
Capital expenditure	3,462	98	_	3,560

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Geographical information

External customers of the Group are located in Singapore, Malaysia and China. The Group carries out its operations in Singapore, Malaysia and China and all the Group's non-current assets are located in Singapore, Malaysia and China.

In presenting the information on the basis of geographical segments, segmental revenue is based on the geographical location of the customers and segmental assets are based on the geographical location of the assets.

	Six months Mar		Full year ended 31 March		
	2024 2023 S\$'000 S\$'000		2024 S\$'000	2023 S\$'000	
Revenue					
Singapore	23,280	19,298	44,916	37,682	
Malaysia	3,007	2,719	5,870	5,330	
China	341	275	665	495	
Discontinued operations	(341)	(275)	(665)	(495)	
Consolidated revenue	26,287	22,017	50,786	43,012	

	31 March 2024 S\$'000	31 March 2023 S\$'000
Non-current assets ⁽¹⁾		
Singapore	46,862	37,964
Malaysia	19,356	20,251
China		9,170
Consolidated total non-current assets	66,218	67,385

⁽¹⁾ Non-current assets information presented above consist of property, plant and equipment, right-of-use assets, investment property, non-current trade and other receivables, investment in associate and intangible asset.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Revenue

5

Revenue	Medicare	centres and nur fees	sing homes	•		- Ancillary fees			
Six months ended 31 March	Home fees S\$'000	Home care and day care and other nursing home services S\$'000	Operating subvention grant S\$'000	Ambulance fees S\$'000	Course fees S\$'000	Management fee S\$'000	Traditional Chinese medicine ("TCM") clinics services S\$'000	Other ancillary services S\$'000	Total S\$'000
2024									
Third parties - Singapore - Malaysia	7,051 2,184	2,080 823	13,125	600 _	17		395	_*	23,268 3,007
- China	9,235	2,903	13,125	600	 17		395	-	26,275
Related corporation - Singapore	9,235	2,903		- 600	 17	<u>12</u> 12		*	<u>12</u> 26,287
		,	,						
2023 Third parties									
- Singapore	5,849	2,011	11,008	-	2	_	416	_*	19,286
 Malaysia China 	1,806	914	_	_	-	_	_		2,720
China	7,655	2,925	11,008	-	2	-	416	_	22,006
Related corporation - Singapore						12			12
- Singapore	7,655	2,925	11,008	_	2	12	416	*	22,018
Full year ended 31 March 2024		<i>J</i> ²	,						
Third parties - Singapore	13,672	4,146	25,628	600	18	_	827	2	44,893
- Malaysia	4,166	1,704		-	-	_		-	5,870
- China			_	-	_	_	_	_	_
	17,838	5,850	25,628	600	18	-	827	2	50,763
Related corporation									
- Singapore		_	_	_	_	23	_	-	23
	17,838	5,850	25,628	600	18	23	827	2	50,786

* Less than S\$1,000

	Medicare o	centres and nurs fees	ing homes	•		Ancillary fee	es ———		
Full year ended 31 March	Home fees S\$'000	Home care and day care and other nursing home services S\$'000	Operating	Ambulance fees S\$'000	Course fees S\$'000	Management fee S\$'000	Traditional Chinese medicine ("TCM") clinics services S\$'000	Other ancillary services S\$'000	Total S\$'000
2023									
Third parties									
- Singapore	11,623	3,884	21,287	-	4	-	861	_*	37,659
- Malaysia	3,516	1,814	_	-	_	-	_	-	5,330
- China	_	_	_	-	_	_	_	-	-
	15,139	5,698	21,287	-	4	-	861	_*	42,989
Related corporation - Singapore	_	_	_	_	_	23	_	_	23
01	15,139	5,698	21,287	-	4	23	861	_*	43,012

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

* Less than S\$1,000

Home fees generally relates to the Medicare Centres and Nursing Homes' contracts with patients in which performance obligations are to provide dedicated nursing home healthcare services to individual patients in Singapore, Malaysia and China. Home care and day care fees generally relates to contracts with patients in which performance obligations are to provide healthcare services to individual patients at their homes and day care centres. Ambulance fees relate to provision of medical and passenger transport services to hospitals and individual patients in Singapore. Course fees relate to contracts with corporate customers in which performance obligations are to provide training for care staffs, nursing home managers and home caregivers in Singapore. Management fee relates to provision of management and consultancy services to related corporations. Related corporations are other related parties not within the Group that are owned by the Group's controlling shareholder. Traditional Chinese Medicine ("TCM") clinic services relate to the offering of TCM services at TCM clinics.

Other ancillary services relate to provision of dressing, rehabilitation services, TCM treatments and other medical related services to individual patients.

Invoices are issued based on contractual terms. The Group has a credit term of 10 to 30 days which is typically short term, in line with market practice, without any financing component. There are no variable considerations, and no obligations for returns or refunds or warranties for healthcare-related services.

Operating subvention grants are government subsidies given to patients and are paid by the Government on behalf of the patients to the Group for the subsidised amounts and is a revenue to the Group. The operating subvention grant scheme requires the Group to set aside a portion of its beds for eligible patients who meet the means test criteria to enjoy the subsidies. These patients are generally older persons who are unable to have adequate level of nursing care required in their own homes, and require supervision or assistance with their daily activities as well as persons who need further care and treatment after being discharged from an acute and/or community hospital.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

The performance obligations for nursing home healthcare services, home care services, management services and training services are generally satisfied over time and revenue is recorded when the services are performed. The performance obligations for ambulance services, TCM and other ancillary services are generally satisfied at a point in time.

6 Other income

		s ended 31 rch	Full year ended 31 March		
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000	
Other government grants:					
- Grants on special employment					
credit, temporary employment					
credit and wages credit scheme	65	140	83	152	
- Grants on staff accommodation	—	49	_	102	
- Grants on Senior Management					
Associate Scheme	_	19	_	19	
- Grants on Jobs Growth Incentive	_	44	26	171	
- Eldercare centre baseline service					
transition grants	60	210	120	390	
- Active Ageing Centre fundings	185	_	352	_	
- Grants on community care salary					
enhancements	1,996	599	2,063	727	
- Grants on Healthcare Hiring In		·		• • •	
Advance Initiatives	_	284	_	284	
- Grant on Workforce					
Development	_	88	_	88	
Rental income	128	135	261	261	
Amortisation of deferred capital					
grants	294	181	435	255	
Service fees	—	—	_	32	
Dividends income from quoted					
securities	_	_	49	_	
Gain on disposal of motor vehicle	201	—	201	—	
Rental subsidy/subvention grants	1,297	1,297	2,593	2,593	
Pre-operations funding	-	1,927	199	2,935	
Furniture and equipment funding	283	327	283	327	
Others	121	177	309	362	
	4,630	5,477	6,974	8,698	

* Less than S\$1,000

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Finance costs, net

7

	Six months end 2024 S\$'000	led 31 March 2023 S\$'000	Full year ende 2024 S\$'000	ed 31 March 2023 S\$'000
Interest income from bank				
deposits	106	179	307	211
Interest income from finance				
lease receivables	_	_	_	_
Exchange gain, net		18	_	12
Finance income	106	197	307	223
Exchange loss, net Interest expense on bank	(3)	_	(1)	-
borrowings	(89)	(137)	(211)	(268)
Unwinding of discount on provision of restoration cost	(7)	(4)	(10)	(7)
Interest expense from lease	(')		(10)	(/)
liabilities	(586)	(439)	(1,079)	(891)
Finance costs	(685)	(580)	(1,301)	(1,166)
Net finance costs	(579)	(383)	(994)	(943)

8 Profit before tax from continuing operations

The following items have been included in arriving at profit for the period/year from continuing operations:

	Six months end 2024 S\$'000			ed 31 March 2023 S\$'000
Write-off of property, plant and equipment Expenses relating to short-term leases presented in "staff costs" and "other	10	47	12	67
operating expenses"	145	100	255	218
Repair and maintenance expenses	853	714	1,566	1,512
Contributions to defined contribution plans included in				
staff costs	714	704	1,321	1,259
Directors' fees	46	90	133	174

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

9 Income tax (credit)/expense

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax (credit)/expense for the six months and full year ended 31 March 2024 and 2023 are:

	Six months end	led 31 March	Full year ended 31 March		
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000	
Current tax expense	526	935	967	1,356	
Deferred tax (credit)/expense	(621)	153	(718)	112	
Income tax (credit)/expense attributable to continuing operations	(95)	1,088	249	1,468	
Income tax expense attributable		1,000		1,408	
to discontinued operations	19	_	19		
Income tax (credit)/expense recognised in profit or loss	(76)	1,088	268	1,468	

10 Property, plant and equipment

During the full year ended 31 March 2024, the Group had total additions to property, plant and equipment of S\$1,807,000 (31 March 2023: S\$3,560,000), out of which S\$300,000 relates to additions to non-current assets of disposal group classified as held for sale.

The Group also acquired S\$2,289,000 of property, plant and equipment as a result of the completion of acquisition of Ambulance Medical Service Pte. Ltd. (Note 22) on 5 March 2024.

11 Right-of-use assets

During the full year ended 31 March 2024, the Group recognised additions to right-of-use assets of \$\$6,613,000 (31 March 2023: \$\$679,000)

12 Investment property

31 March 2024 S\$'000	31 March 2023 S\$'000
7,554	8,092
	(538) 7,554
	2024 S\$'000

Investment property comprises a freehold land that is leased to a third party during the year. The lease contains an initial non-cancellable period of three years with option to renew for additional three years.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Amounts recognised in profit or loss

	Six months end	Six months ended 31 March		ed 31 March	
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000	
Rental income	129	128	261	260	
Direct operating expenses	(3)	(3)	(5)	(6)	

Investment property is measured at cost but for which fair value is disclosed

The fair value of the investment property amounted to S\$7,168,000 (31 March 2023: S\$7,546,000).

The fair value of investment property located in Malaysia is determined by an independent valuer who has appropriate recognised professional qualifications and recent experience in the location and category of properties being valued.

The investment property is categorised under Level 3 of the fair value measurement hierarchy. The fair value of investment property is based on market value using direct comparison method. It is an estimated amount for which a property could be exchanged on the date of the valuation between a willing buyer and a willing seller in an arm's length transaction after proper marketing wherein the parties had each acted knowledgeably. Due adjustments for difference between the properties and the comparables in terms of location, tenure, size, shape, floor level, age and conditions of properties and date of transactions affecting its value were made in arriving at the fair value of investment property.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

13 Trade and other receivables

	Group		Company		
	31 March 2024 S\$'000	31 March 2023 S\$'000	31 March 2024 S\$'000	31 March 2023 S\$'000	
Trade receivables – third parties	3,150	1,775	_	_	
Less: Impairment losses	(285)	(273)	_	-	
-	2,865	1,502			
Trade receivables – subsidiaries	_	_	5,065	3,638	
Impairment losses	_	_	(1,055)	(690)	
	2,865	1,502	4,010	2,948	
Receivables for operating subvention grants	2 261	1 627			
Aggregate of trade receivables and receivables for operating	2,261	1,637	_		
subvention grants	5,126	3,139	4,010	2,948	
Other government grant					
receivables	3,447	2,268	77	171	
Other receivables	890	207	867	45	
Staff advances	14	29	_	-	
Deposits	2,729	1,991	768	766	
Non-trade amounts due from subsidiaries			2,533	2,395	
Impairment losses	_	-	2,333 (678)	(586)	
-	12 200	7.624	· /	· /	
Financial assets at amortised cost	12,206	7,634	7,577	5,739	
Prepayments	472	393	172	271	
-	12,678	8,027	7,749	6,010	
Non-current	2,302	1,736	3,275	2,892	
Current	10,376	6,291	4,474	3,118	
_	12,678	8,027	7,749	6,010	

Trade receivables are non-interest bearing and are generally on terms of 10-30 days.

Non-trade amounts due from subsidiaries are unsecured, interest-free and repayable on demand.

The Group's non-current amounts relate mainly to security deposits paid for leased premises. The security deposits are interest-free and are refundable at lease expiry or earlier termination of the lease.

The Company's non-current amounts relate mainly to trade amounts due from subsidiaries, which are unsecured, interest-free, repayable on demand and not expected to be repaid within 12 months.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

14 Share capital

	Number of shares		Amount	
	31 March 31 March 2024 2023		31 March 2024 S\$'000	31 March 2023 S\$'000
Group and Company				
Issued and fully paid ordinary shares, at par value:				
In issue at beginning of the year	257,000,000	257,000,000	28,255	28,255
Shares issued during the year				
(Note 22)	8,910,891	_	1,728	_
In issue at end of the year	265,910,891	257,000,000	29,983	28,255

Ordinary shares

The holders of ordinary shares are entitled to receive dividends as declared from time to time, and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

As at 31 March 2024 and 31 March 2023, there were no treasury shares held by the Company and there were no subsidiary holdings.

15 Reserves

Currency translation reserve

The currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations.

Merger reserve

Merger reserve represents reserve arising from the business combinations through common control.

Dividends

During the full year period ended 31 March 2024, the Group declared final dividend in amount of S\$1,130,800 (S\$0.0044 per ordinary share) for FY2023 and interim dividend in amount of S\$591,100 (S\$0.0023 per ordinary share) for FY2024. The dividends were fully paid.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

16 Net asset value per share

	Group		Company	
	31 March 2024	31 March 2023	31 March 2024	31 March 2023
Net asset value per ordinary				
share (in cents)	16.70	15.08	16.97	16.64

17 Earnings per share

Basic earnings per share

The basic earnings per share is calculated by dividing the Group's profit for the period/year, attributable to owner of the Company by the weighted-average number of ordinary shares outstanding and on a fully diluted basis during the year.

The following tables reflect the profit and share data used in the computation of basic earnings per share for the period/years ended 31 March:

	Six months ended 31 March		Full year ended 31 March	
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000
Profit from continuing				
operations, net of tax	4,431	3,983	6,298	5,832
Profit/(loss) from discontinued				
operations, net of tax	312	(822)	124	(983)
Profit for the period/year				
attributable to owner of				
the Company	4,743	3,161	6,422	4,849
the Company	4,743	3,161	6,422	4,849

	Six months en	ded 31 March	Full year ended 31 March	
	2024 No. of shares	2023 No. of shares	2024 No. of shares	2023 No. of shares
Weighted-average number of ordinary shares at end of the period/year	258,314,721	257,000,000	257,659,162	257,000,000

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

	Six months ended 31 March		Full year ended 31 March	
	2024	2023	2024	2023
Earnings per share for the period/year from continuing operations attributable to owner of the Company				
Basic and diluted earnings per share (cents)	1.72	1.55	2.44	2.27
Earnings per share for the period/year Basic and diluted earnings per share (cents)	1.84	1.23	2.49	1.89

Diluted earnings per share

As at 31 March 2024 and 2023, there were no outstanding dilutive potential ordinary shares.

18 Loans and borrowings

	31 March 2024 S\$'000	31 March 2023 S\$'000
Non-current liabilities		
Secured bank loans	1,242	1,798
	1,242	1,798
Current liabilities		
Unsecured bank loans	1,913	2,815
Secured bank loans	469	470
	2,382	3,285
	3,624	5,083

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Terms and debt repayment schedule

The terms and conditions of outstanding loans and borrowings are as follows:

	Note	Currency	Nominal interest rate %	Year of maturity	Face value S\$'000	Carrying amount S\$'000
31 March 2024 Group						
-			Base lending rate –			
Secured bank loans Unsecured revolving	В	MYR	1.25%	2027	1,711	1,711
credit	С	MYR	Cost of funds $+ 1.50\%$	2024	1,913	1,913
				_	3,624	3,624
31 March 2023 Group						
Unsecured bank loans	А	SGD	SIBOR + 2% Base lending rate –	2023	801	801
Secured bank loans Unsecured revolving	В	MYR	1.25%	2027	2,268	2,268
credit	С	MYR	Cost of funds + 1.50%	2023	2,014	2,014
					5,083	5,083

- A) As at 31 March 2023, the bank loan is unsecured, and the Company shall maintain on a consolidated basis, a Gross Debt / EBITDA ratio of not more than 3.50 times. The loan was fully repaid during the year ended 31 March 2024.
- B) The bank loan was secured by the Group's freehold land and building amounting to S\$7,856,000 (31 March 2023: S\$8,448,000).
- C) As at 31 March 2024 and 31 March 2023, the bank loan is unsecured and a subsidiary of the Group shall maintain a tangible net worth of not less than RM40,000,000 and gearing ratio shall not exceed 0.75 times.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

19 Trade and other payables

	Group		Company		
	31 March 2024 S\$'000	31 March 2023 S\$'000	31 March 2024 S\$'000	31 March 2023 S\$'000	
Trade payables – third parties	1,257	1,050	_	_	
Non-trade amount due to					
subsidiaries	_	_	181	1,011	
Accrued operating expenses	2,825	2,916	1,314	927	
Interest payables	_	3	_	_	
Other payables	682	666	49	81	
Payables to suppliers of property,					
plant and equipment	331	1,166	330	330	
Refundable deposits	1,530	1,465	_	-	
Financial liabilities at amortised					
cost	6,625	7,266	1,873	2,349	
Deferred grant income	122	321	_	_	
Liability for short-term accumulated compensated					
absences	308	140	146	80	
Home fees collected in advance	99	189			
	7,154	7,916	2,020	2,429	

Trade payables are non-interest bearing and are generally on terms of 30 days.

Non-trade amounts due to subsidiaries are unsecured, interest-free and repayable on demand.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

20 Related parties

Key management personnel compensation

Key management personnel of the Group are those persons having the authority and responsibility for planning, directing and controlling the activities of the Group. The Board of Directors and senior management team are considered as key management personnel.

	Six months end 2024 S\$'000	led 31 March 2023 S\$'000	Full year ende 2024 S\$'000	ed 31 March 2023 S\$'000
Post-employment benefits Short term employee benefits	17	23	44	44
including director fees	591	590	1,326	1,147
Non-monetary benefit	50	139	126	152
	658	752	1,496	1,343

Other related party transactions

Other than disclosed elsewhere in the financial statements, transactions with related parties are as follows:

	Six months end	Six months ended 31 March		d 31 March
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000
Related corporations*				
Management fee income	(9)	(9)	(19)	(19)
Rental income	(2)	(2)	(5)	(5)

*Related corporations are other related parties not within the Group that are owned by the majority shareholder.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

21 Discontinued operations and disposal group held for sale

During the year, the Group undertook a strategic review of its China operations and has committed in a sale plan to partially dispose 11% and 21% of its interest in China subsidiaries, Chongqing Yikang Bailingbang Eldercare Co., Ltd., Chongqing Changshou Yikang Bailingbangyanjia Eldercare Co., Ltd. ("China subsidiaries") and full interest in the associate, Sichuan Guangda Bailingbang Yikang Eldercare Co., Ltd. (collectively known as "China Group") for a total consideration of approximately S\$755,000. The consideration is expected to be paid by way of cash over three consecutive years and was arrived at on a willing-buyer, willing-seller basis. The consideration is more than the apportioned net asset value of China subsidiaries and associate based on the interest being disposed off, which amounted to S\$324,000 as at 31 March 2024. Following the divestment, Chongqing Yikang Bailingbang Eldercare Co., Ltd. and Chongqing Changshou Yikang Bailingbangyanjia Eldercare Co., Ltd.. would cease to be subsidiaries of the Company and the Group will retain a non-controlling interest of 49% in both entities. The divestment is expected to be completed by June 2024.

As at 31 March 2024, the assets and liabilities related to the China subsidiaries had been presented in the balance sheet as "assets of disposal group classified as held for sale" and "liabilities directly associated with disposal group classified as held for sale" and its results are presented separately on the income statement as "profit/(loss) from discontinued operations, net of tax".

The results of China subsidiaries for the period/year ended 31 March are as follows:

	Chongqing Yikang Bailingbang Eldercare Co., Ltd. S\$'000	Chongqing Changshou Yikang Bailingbang yanjia Eldercare Co., Ltd. S\$'000	Total S\$'000
Six months ended 31 March 2024			
Revenue	233	108	341
Profit/(loss) for the period	786	(228)	558
Other comprehensive income	(8)	(4)	(12)
Total comprehensive income	778	(233)	545
Attributable to non-controlling interests			
- Profit/(loss) for the period	315	(69)	246
- Other comprehensive income	(3)	(1)	(4)
- Total comprehensive income	312	(70)	242

Notes to the condensed consolidated financial statements	
For the six months and full year period ended 31 March 2024	

	Chongqing Yikang Bailingbang Eldercare Co., Ltd. S\$'000	Chongqing Changshou Yikang Bailingbang yanjia Eldercare Co., Ltd. S\$'000	Total S\$'000
Full year ended 31 March 2024			
Revenue	484	181	665
Profit/(loss) for the year	766	(479)	287
Other comprehensive income	(27)	(33)	(60)
Total comprehensive income	739	(512)	227
Attributable to non-controlling interests			
- Profit/(loss) for the year	307	(144)	163
- Other comprehensive income	(11)	(10)	(21)
- Total comprehensive income	296	(154)	142
Six months ended 31 March 2023 Revenue Loss for the period Other comprehensive income Total comprehensive income Attributable to non-controlling interests - Loss for the period - Other comprehensive income - Total comprehensive income	266 (1,036) (73) (1,109) (415) (29) (444)	9 (286) (36) (322) (86) (11) (97)	$275 \\ (1,322) \\ (109) \\ (1,431) \\ \hline (501) \\ (40) \\ (541) \\ \hline $
Full year ended 31 March 2023 Revenue	486	9	495
Loss for the year	(1,075)	(482)	(1,557)
Other comprehensive income	(134)	(90)	(224)
Total comprehensive income	(1,209)	(572)	(1,781)
Attributable to non-controlling interests	(100)	· · · · · ·	
- Loss for the year	(430)	(145)	(575)
- Other comprehensive income	(53)	(27)	(80)
- Total comprehensive income	(483)	(172)	(655)

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

The following items have been included in arriving at profit/loss before discontinued operations for the period/year:

	Six months ended 31 March		Full year ended 31 Mar	
	2024 S\$'000	2023 S\$'000	2024 S\$'000	2023 S\$'000
(Reversal of)/impairment losses on property, plant and	(222)			
equipment, net Impairment losses on right-of-	(232)	568	(232)	568
use assets, net	47	380	47	380

The major classes of the assets and liabilities of China subsidiaries classified as held for sale and the related translation reserve as at 31 March 2024 are as follows:

		Chongqing Yikang Bailingbang Eldercare Co., Ltd. S\$'000	Chongqing Changshou Yikang Bailingbang yanjia Eldercare Co., Ltd. S\$'000	Total S\$'000
Assets	Assets			
Property, plant and equipment 988 2,321 3,309	Property, plant and equipment	988	2,321	3,309
		711	4,897	5,608
Trade and other receivables113593706	Trade and other receivables	113	593	706
Cash and cash equivalents 1,167 287 1,454	Cash and cash equivalents	1,167	287	1,454
Assets of disposal group classified as held for sale 2,979 8,098 11,077	Assets of disposal group classified as held for sale	2,979	8,098	11,077
Liabilities	Liabilities			
Lease liabilities 862 5,494 6,356	Lease liabilities	862	5,494	6,356
Deferred capital grants 326 1,002 1,328	Deferred capital grants	326	1,002	1,328
Trade and other payables4228881,310	Trade and other payables	422	888	1,310
Liabilities directly associated with disposal group	Liabilities directly associated with disposal group			
classified as held for sale 1,610 7,384 8,994	classified as held for sale	1,610	7,384	8,994
Equity	Equity			
		(41)	(133)	(174)
Reserves of disposal group classified as held for sale (41) (133) (174)	Reserves of disposal group classified as held for sale	e (41)	(133)	(174)

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

The cash flows attributable to China subsidiaries for the year ended 31 March 2024 are as follows:

	Chongqing Yikang Bailingbang Eldercare Co., Ltd. S\$'000	Chongqing Changshou Yikang Bailingbang yanjia Eldercare Co., Ltd. S\$'000	Total S\$'000
31 March 2024			
Cash flows generated from/(used in) operating activities	106	(25)	81
Cash flows used in investing activities	(73)	(477)	(550)
Cash flows from financing activities	_	498	498
Net increase/(decrease) in cash and cash equivalents	33	(4)	29
31 March 2023			
Cash flows generated from operating activities	70	305	375
Cash flows (used in)/generated from investing			
activities	(310)	60	(250)
Cash flows used in financing activities	(35)	(200)	(235)
Net (decrease)/increase in cash and cash equivalents	(275)	165	(110)

Earnings/(loss) per share disclosure

Earnings/(loss) per share (cents per share) from discontinued operations attributable to owner of the Company are as follows:

	Six months ended 31 March		Full year ended 31 March	
	2024	2023	2024	2023
Basic and diluted earnings/(loss) per share (cents)	0.12	(0.32)	0.05	(0.38)

The basic earnings/(loss) per share from discontinued operations are calculated by dividing the profit/(loss) from discontinued operations, net of tax, attributable to owners of the Company by the weighted-average number of ordinary shares outstanding during the year. As at 31 March 2024 and 2023, there were no outstanding dilutive potential ordinary shares. These earnings/(loss) and share data are presented in tables in Note 17.

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

In conjunction with the committed sale plan, the carrying amount of the Group's interest in its associate, Sichuan Guangda Bailingbang Yikang Eldercare Co., Ltd. was presented as assets held for sale and its share of results are presented separately on income statement as "profit/(loss) from discontinued operations, net of tax".

The following summarised financial information for the associate:

	Six months ende 2024	ed 31 March 2023	Full year e 2024	nded 31 March 2023
Revenue (Loss)/profit for the period/year, representing	-	439	538	721
total comprehensive income		(112)	14	(149)
				31 March 2024 S\$'000
Non-current assets				32
Current assets				701
Non-current liabilities				-
Current liabilities				(618)
Net assets				115
Carrying amount of interest in associate as at 31 March 20 Presented as asset held for sal	24			23
2024				23

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

22 Intangible asset

Acquisition of Ambulance Medical Service Pte. Ltd.

On 5 March 2024, the Group completed its acquisition of 100% of the equity interest in Ambulance Medical Service Pte. Ltd. ("AMS"). AMS was established in 2007 and is in the business of providing of emergency ambulance and medical evacuation services, as well as event medical standby services. As disclosed in the circular to shareholders dated 6 December 2023, the acquisition of AMS and the diversification of the Group's core business to include the provision of emergency ambulance services and medical transport services will allow the Group to diversify its business in order to enhance its service offerings that are complementary to the Group's existing core business and integrate with its existing network of medical centres and nursing homes.

The provisional fair value of the identifiable assets and liabilities of AMS as at the date of acquisition were:

	S\$'000
Assets	
Property, plant and equipment	2,289
Trade and other receivables	1,293
Cash and cash equivalents	172
	3,754
Liabilities	
Deferred tax liabilities	(33)
Current tax payable	(274)
Trade and other payables	(675)
1.5.	(982)
Total identifiable net assets at provisional fair value	2,772
Provisional goodwill arising from acquisition	5,110
Purchase consideration transferred	7,882
Consideration transferred for the acquisition of AMS:	
Cash paid	7,000
Issuance of shares of the Company	1,728
Amount to be refunded to the Company	(846)
I a state i	7,882
Effect of the construction of AMC an early flower	
Effect of the acquisition of AMS on cash flows:	(7,000)
Consideration settled in cash	(7,000)
Less: Cash and cash equivalents of subsidiary acquired	172
Net cash outflow on acquisition	(6,828)

Notes to the condensed consolidated financial statements For the six months and full year period ended 31 March 2024

Equity instruments issued

In connection with the acquisition of AMS, the Company issued 8,910,891 ordinary shares with a fair value of S\$0.19 each. The fair value of these shares is the published price of the shares at the acquisition date.

Amount to be refunded to the Company

Based on the sale and purchase agreement, the final purchase price is subject to net cash/(debt) and working capital adjustments. The Group estimates that the adjustment to the final purchase price is a decrease of \$\$\$846,000, which would be payable by the seller to the Company. The final purchase price exercise is expected to be finalised in June 2024.

Acquisition-related costs

The Group incurred acquisition-related costs related of S\$312,000 on legal fees and due diligence costs. These costs have been included in the "other operating expenses" line item in the Group's statement of comprehensive income for the full year ended 31 March 2024.

Trade and other receivables

Trade and other receivables acquired amounted to S\$1,293,000, which is also the gross amount. It is expected that the full contractual amount of receivables can be collected.

Provisional goodwill arising from acquisition

The goodwill of S\$5,110,000 represents synergies expected to be achieved from the comprehensive integration of the emergency ambulance services business into the existing healthcare ecosystem established within the Group. The goodwill is provisional and pending finalisation of the purchase price allocation exercise to be completed in FY2025.

Impact of the acquisition on profit or loss

From the date of acquisition until 31 March 2024, AMS has contributed revenue from continuing operations of S\$612,000 and profit before tax from continuing operations of S\$48,000 to the Group's results. If the acquisition had taken place at the beginning of the reporting period, the Group estimates that consolidated revenue from continuing operations would have been S\$58,130,000 and the consolidated profit before tax from continuing operations would have been S\$7,160,000.

23 Subsequent events

On 13 May 2024, the Group via a wholly owned subsidiary, Econ Healthcare (China) Pte. Ltd. entered into a sale and purchase agreement to partially dispose 5.1% of its interest in the associate, Sichuan Guangda Bailingbang Yikang Eldercare Co., Ltd. for a consideration of S\$95,000. The consideration is to be paid by way of cash over three consecutive years and was arrived at on a willing-buyer, willing-seller basis. The consideration is more than the apportioned net asset value of associate based on the interest being disposed off, which amounted to S\$5,800 as at 31 March 2024.

Other information required for Full Year Announcement

1 Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of the Group as at 31 March 2024 and the related consolidated profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year ended 31 March 2024 and selected explanatory notes have not been audited or reviewed by the auditors.

2 Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)

Not applicable as the figures have not been audited or reviewed by the auditors.

Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.
This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable, there is no adverse opinion, qualified opinion or disclaimer of opinion in relation to the latest financial statements.

A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

(A) Statement of comprehensive income

FY2024 vs FY2023

Revenue

Revenue increased by 18.1% or S\$7.8 million, from S\$43.0 million in FY2023 to S\$50.8 million in FY2024 mainly due to an increase in S\$7.2 million in Medicare centres and nursing home fees and S\$0.6 million in ancillary fees.

The increase in Medicare centres and nursing home fees was attributable to an (i) increase of S\$6.7 million from Singapore comprising S\$4.1 million attributable to the fully ramped up operations of the ECON Care Residences (Henderson), and S\$2.6 million attributable to an improvement in the Group's homecare business and fees increment, (ii) increase of S\$0.5 million from Malaysia as a result of a net increase in the bed occupancy of 31 for both ECON Medicare Centre and Nursing Home – Puchong and ECON Medicare Centre and Nursing Home – Taman Perling.

Other information required for Full Year Announcement

Ancillary fees increased by S\$0.6 million from S\$0.9 million in FY2023 to S\$1.5 million in FY2024 mainly due to an increase in ambulance fees, attributable in part to completion of the Group's acquisition of Ambulance Medical Service Pte. Ltd. ("AMS") on 5 March 2024.

As at 31 March 2024, our monthly average bed capacity from continuing operations stood at 1,419. The Group had achieved an overall bed occupancy of 90.7% in FY2024, compared to 79.9% in FY2023, which was mainly due to an increase in the occupancy rates for ECON Care Residences (Henderson).

Other income

Other income decreased by 19.8%, or S\$1.7 million from S\$8.7 million in FY2023 to S\$7.0 million in FY2024. The decrease was mainly attributed to a decrease in (i) pre-operations funding of S\$2.7 million for the purpose of facilitating the ramping up of operations for ECON Care Residences (Henderson), (ii) jobs growth incentive grants of S\$0.1 million, (iii) staff accommodation grants of S\$0.1 million, (iv) workforce development grants of S\$0.1 million, and (v) grants on healthcare hiring in advance initiatives of S\$0.3 million. These decreases were offset by the increase in grants on community care salary enhancements of S\$1.3 million, amortisation of deferred capital grants of S\$0.2 million and gain on disposal of motor vehicle of S\$0.2 million.

Supplies and consumables

Supplies and consumables increased by 10.4%, or S\$0.6 million, from S\$6.1 million in FY2023 to S\$6.7 million in FY2024. The increase was mainly due to increase in the purchase of consumables of S\$0.5 million for residents for ECON Care Residences (Henderson) and S\$0.1 million for ECON Medicare Centre and Nursing Home – Puchong and ECON Medicare Centre and Nursing Home – Taman Perling.

Staff costs

Staff costs increased by 20.2%, or S\$4.7 million from S\$23.0 million in FY2023 to S\$27.7 million in FY2024. The increase is mainly due to (i) S\$1.6 million of staff costs incurred for increase in headcount of ECON Care Residences (Henderson), (ii) S\$1.9 million of staff costs incurred for increase in headcount and salary increments in the remaining nursing homes and homecare, (iii) increase in headcount for support function of S\$0.8 million, and (iv) S\$0.4 million of staff costs incurred for the consolidation of AMS.

Depreciation of property, plant and equipment

Depreciation of property, plant and equipment increased by 9.8%, or S\$0.1 million from S\$1.2 million in FY2023 to S\$1.3 million in FY2024. The increase is mainly due to depreciation charges from the acquisition of property, plant and equipment of AMS.

Depreciation of right-of-use assets

Depreciation of right-of-use assets remained fairly comparable at S\$7.5 million for both FY2023 and FY2024.

Utilities expenses

Utilities expense remained fairly comparable at S\$1.5 million for both FY2023 and FY2024.

Other information required for Full Year Announcement

Other operating expenses

Other operating expenses increased by 23.1%, or S\$1.0 million, from S\$4.4 million in FY2023 to S\$5.4 million in FY2024. The increases were mainly due to increase in (i) professional fees of S\$0.3 million incurred by the Group for the acquisition of AMS, (ii) professional fees of S\$0.3 million in relation to statutory compliance fees such as sustainability reporting and audit fees, (iii) consolidation of AMS other operating expenses of S\$0.1 million and (iv) unclaimable GST expenses of S\$0.3 million that the Group has to absorb due to increase in subsidy home fees.

Finance costs, net

Net finance costs increased by 5.4%, or S\$0.1 million, from S\$0.9 million in FY2023 to S\$1.0 million in FY2024 mainly due to higher finance costs from leases, as there were leases being renewed during the year.

Profit before tax from continuing operations

Profit before tax from continuing operations decreased by 8.8%, or S\$0.6 million, from S\$7.2 million in FY2023 to S\$6.6 million in FY2024. The decrease in profit before tax from continuing operations for FY2024 was mainly brought about by the decrease in other income, mainly due to decrease in pre-operations fundings of S\$2.7 million, grants on staff accommodation of S\$0.1 million, grants on job growth incentive of S\$0.1 million, and professional fees of S\$0.3 million relating to the acquisition of AMS. These decreases were offset by increase in grants on community care salary enhancements of S\$1.5 million and gain on disposal of motor vehicle of S\$0.2 million.

Excluding the abovementioned exceptional items, the normalised profit before tax from continuing operations for FY2024 is S\$4.1 million compared to the normalised profit before tax from continuing operations of S\$3.0 million for FY2023. The normalised profit before tax from continuing operations had increased from 6.9% for FY2023 to 8.1% for FY2024.

Tax expense

Tax expense decreased by 83.0%, or S\$1.2 million, from S\$1.5 million in FY2023 to S\$0.2 million in FY2024. This is mainly due to lower tax expenses, as there are tax allowances, such as merger and acquisition allowance, claimable in Singapore, and reversal of deferred tax liabilities in Malaysia as the taxable temporary differences would be realised in the next year.

Discontinued operations

Discontinued operations relate to the China subsidiaries and associate as the Group had classified the China subsidiaries and associate as Discontinued operations and disposal group held for sale (Note 21).

Profit from continuing operations attributable to owner of the company (PATMI)

As a result of the foregoing, the Group's PATMI increased by S\$0.5 million, from S\$5.8 million in FY2023 to S\$6.3 million in FY2024. PATMI margin decreased from 13.6% in FY2023 to 12.4% in FY2024.

Earnings per share (EPS) for the year from continuing operations on a fully diluted basis for FY2024 was 2.44 cents compared to 2.27 cents for FY2023.

Other information required for Full Year Announcement

Net asset value (NAV) per share was 16.70 cents as at 31 March 2024 compared to 15.08 cents as at 31 March 2023.

(B) Statement of financial position

Non-current assets

As at 31 March 2024, non-current assets of S\$66.6 million accounted for 63.2% of the Group's total assets. Non-current assets comprised the following:

- property, plant and equipment, which amounted to S\$16.6 million, and comprised freehold land and buildings, properties under construction, leasehold improvements and renovations, nursing homes equipment, ambulances and medical equipment, furniture, fittings and office equipment, computers and accessories and motor vehicles;
- (ii) right-of-use assets, which amounted to S\$35.1 million, and comprised nursing homes, office premise and health and wellness centres, office equipment, staff accommodation and motor vehicles;
- (iii) investment property, which amounted to S\$7.2 million, and is related to a freehold land owned by the Group in Cheras, Malaysia. The land was leased to a third party lessee to operate an education centre;
- (iv) trade and other receivables, which amounted to S\$2.3 million, and is related to security deposits paid to our landlords and utilities providers;
- (v) deferred tax assets, which amounted to S\$0.4 million, in relation to lease accounting, provisions and tax loss carry-forwards; and
- (vi) intangible asset of S\$5.1 million, arising from the recognition of the provisional goodwill from the consolidation of AMS, pending the purchase price exercise to be finalised in FY2025.

Non-current assets decreased by S\$0.9 million from S\$67.5 million as at 31 March 2023 to S\$66.6 million as at 31 March 2024. This was mainly due to (i) recognition of the provisional goodwill of S\$5.1 million from the consolidation of AMS, (ii) consolidation of AMS non-current assets of S\$2.5 million, (iii) increase in deferred tax assets by S\$0.3 million, and (iv) increase in trade and other receivables of S\$0.6 million due to deposits paid to landlords for leases. These increases are offset by S\$9.0 million of non-current assets of the China subsidiaries being presented as "assets of disposal group classified as held for sale" under current assets and decrease in investment property of S\$0.4 million due to translation differences as Singapore dollar appreciate against the Malaysian Ringgit.

Current assets

As at 31 March 2024, current assets of S\$38.8 million accounted for 36.8% of total assets. Current assets mainly comprised the following:

- (i) trade and other receivables, which amounted to S\$10.4 million, comprising S\$2.9 million of net third party trade receivables, S\$2.3 million of receivables for operating subvention grants, S\$3.4 million of other government grant receivables, S\$0.5 million prepayments, and cumulatively accounted for 87.5% of total trade and other receivables;
- (ii) investment in quoted securities, which amounted to S\$1.1 million;
- (iii) cash and short-term deposits, which amounted to S\$16.2 million;
- (iv) current tax assets, which amounted to S\$0.1 million; and
- (v) assets of disposal group classified as held for sale, which amounted to S\$11.1 million, comprising the assets of China subsidiaries.

Other information required for Full Year Announcement

Current assets increased by \$\$7.0 million from \$\$31.8 million as at 31 March 2023 to \$\$38.8 million as at 31 March 2024. This was due to current and non-current assets of \$\$11.1 million of China subsidiaries being presented as "assets of disposal group classified as held for sale" under current assets, increase in trade and other receivables of \$\$4.1 million mainly due to increase of \$\$2.0 million of trade receivables and operating subvention grants, and increase in other government receivables of \$\$1.2 million, such as grants on community care salary enhancements and furniture and equipment fundings for ECON Care Residences (Henderson), and other receivables of \$\$0.8 million relating to the refund of consideration for AMS acquisition, pending the final purchase price exercise and increase of \$\$0.3 million in investment in quoted securities. These increases were offset by \$\$8.4 million decrease in cash and bank balances mainly due to acquisition of AMS and dividends payment during the year.

Non-current liabilities

As at 31 March 2024, the Group's non-current liabilities of S\$34.3 million accounted for 56.3% of total liabilities. Non-current liabilities mainly comprised the following:

- (i) loans and borrowings, which amounted to S\$1.2 million, and is related to funding for the expansion of Group's operations;
- (ii) deferred tax liabilities, which amounted to S\$23,000, and is related to differences arising from the recognition of depreciation expenses for property, plant and equipment after the offsetting of tax losses carried forward;
- (iii) deferred capital grants, which amounted to S\$2.6 million, and relating to government grants accrued or received for the purpose of equipping and furnishing the nursing homes.
- (iv) provision for restoration costs, which amounted to S\$0.7 million, and is related to the estimated costs of reinstating leased premises to their original state upon termination or expiration of the leases; and
- (v) lease liabilities, which amounted to S\$29.7 million, being the non-current portion of the future lease payments.

The decrease in non-current liabilities by 17.7% or S\$7.4 million, from S\$41.6 million as at 31 March 2023 to S\$34.2 million as at 31 March 2024 was due to S\$7.4 million of noncurrent liabilities of the China subsidiaries being presented as "liabilities directly associated with disposal group classified as held for sale" under current liabilities, and decrease in loan and borrowings of S\$0.5 million attributable to repayment. These decreases were offset by increase in provision for restoration costs by S\$0.1 million.

Current liabilities

As at 31 March 2024, the Group's current liabilities of S\$26.6 million accounted for 43.7% of total liabilities. Current liabilities mainly comprised the following:

- (i) loans and borrowings, which amounted to S\$2.4 million, and is related to funding for the expansion of the Group's operations and general working capital purposes;
- (ii) trade and other payables, which amounted to S\$7.2 million, comprising S\$1.5 million of refundable deposits received from residents, S\$1.3 million of trade payables and S\$2.8 million of accrued operating expenses, S\$0.1 million of deferred grant income and cumulatively accounted for 80.2% of total trade and other payables;
- (iii) lease liabilities, which amounted to S\$7.0 million, being the present value of the future lease payments; and
- (iv) current tax liabilities, which amounted to S\$1.1 million.

Other information required for Full Year Announcement

Current liabilities increased by S\$7.5 million, from S\$19.1 million as at 31 March 2023 to S\$26.7 million as at 31 March 2024. This was due to current and non-current liabilities of S\$9.0 million of the China subsidiaries being presented as "liabilities directly associated with disposal group classified as held for sale" under current liabilities, and increase in lease liabilities of S\$0.2 million. These were offset with decrease in loan and borrowings of S\$0.9 million attributable to repayments and decrease in trade and other payables by S\$0.7 million.

(C) Statement of cash flows

Cash flow before changes in working capital for FY2024 amounted to S\$16.4 million. Net cash generated from operations was S\$13.9 million due to decrease in trade and other receivables of S\$2.7 million and increase in trade and other payables of S\$0.1 million. As a result, net cash generated from operating activities after adjusting for cash paid for tax was S\$12.7 million.

Net cash flow used in investing activities was S\$7.8 million in FY2024. Net cash flows used were primarily for acquisition of subsidiary of S\$6.8 million, purchase of property, plant and equipment amounting to S\$1.8 million, investment in quoted securities of S\$2.3 million. These were offset with the proceeds of disposal of quoted securities of S\$1.9 million, capital grants received of S\$0.8 million and interest received of S\$0.3 million.

Net cash flow used in financing activities was S\$11.9 million in FY2024. This was attributable to the repayment of bank borrowings and lease liabilities of S\$1.3 million and S\$7.4 million respectively, interest paid of S\$1.6 million and dividends paid of S\$1.7 million. These decreases were offset by increase in capital contribution by non-controlling interests of S\$0.1 million.

Overall, the Group reported a net decrease in cash and cash equivalents of S\$7.1 million for FY2024, ending the period with cash and cash equivalents of S\$17.6 million.

5 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable, there has been no forecast or prospect statement disclosed to shareholders previously.

Other information required for Full Year Announcement

6 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

The Ministry of Health Singapore (MOH) in February 2024 published salary guidelines for the community care sector, aimed to maintain the sector's market competitiveness and provide greater transparency on sector wages. A long-term retention scheme where nurses will receive retention payouts over the next 20 years of their career was also announced in the same month. In March 2024, the Minister of Human Resources, Malaysia announced that the Malaysia government will review the minimum wage this year. While these recent developments may introduce cost pressures for businesses, the Company views them as investments in the sector's most valuable asset: its people. Fair compensation not only attracts skilled individuals but also fosters job satisfaction and engagement, ultimately enhancing service quality and patient care.

While the Group is cautiously optimistic about the future and recognizes the inherent uncertainties and risks, the Group remains steadfast in its dedication to enhancing the quality of life for its elderly clients and supporting their families with unwavering integrity and professionalism.

The Group will also actively explore opportunities, including strategic partnerships and divestments, to reinforce its position as a leading player in the healthcare industry in the region, enhance its capabilities, broaden its service offerings and enhance value for shareholders in the long term.

7 Dividend

(a) Whether an interim (final) ordinary dividend has been declared (recommend); and

Yes. While the Company does not have a fixed dividend policy, as disclosed in the offer document dated 9 April 2023 issued in connection with the Company's initial public offering, the Board intends to recommend and distribute dividends of at least 35% of its net profit after tax attributed to shareholders generated in each of FY2021, FY2022 and FY2023, as the Group wishes to reward its Shareholders for participating in the Group's growth.

	FY2024 S\$'000
Ordinary shares (tax exempt 1-tier)	
- Interim (0.23 Singapore cent per share)	591
- Final (0.63 Singapore cent per share)	1,675
Total annual dividend	2,266

(b)(i) Amount per share (in cents)

Other information required for Full Year Announcement

(b)(ii) Amount per share (in cents) for the previous corresponding period

	FY2023 S\$'000
Ordinary shares (tax exempt 1-tier)	
- Interim (0.23 Singapore cent per share)	591
- Final (0.44 Singapore cent per share)	1,131
Total annual dividend	1,722

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).

Tax exempt one-tier.

(d) The date the dividend is payable

2 September 2024

(e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined

Notice is hereby given that the Register of Members and the Transfer Books of the Company will be closed on 19 August 2024 ("Record Date") for the purpose of determining members' entitlement to the interim dividend.

Duly completed registrable transfers received by the Company's Share Registrar, In.Corp Corporate Services Pte. Ltd., 30 Cecil Street #19-08 Prudential Tower Singapore 049712, up to 5.00 p.m. on 19 August 2024 will be registered before entitlements to the dividend are determined.

(f) If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

Not applicable, the Group intends to declare a final dividend in respect of FY2024.

Other information required for Full Year Announcement

(g) A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:

	FY2024 S\$'000	FY2023 S\$'000		
Ordinary	2,266	1,722		
Preference	-	—		
Total:	2,266	1,722		

8 Breakdown of revenue and profit after tax

	Group		
	FY2024 (S\$'000)	FY2023 (S\$'000)	Change (%)
(a) Sales reported for first half year	24,499	20,995	16.7
(b) Operating profit after tax before deducting minority interests reported for first half year	1,570	1,575	(0.3)
(c) Sales reported for second half year	26,287	22,017	19.4
(d) Operating profit/(loss) after tax before deducting minority interests reported for second half year	5,054	2,587	95.4

Other information required for Full Year Announcement

9 If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

Name of Interested Person	Aggregate value (\$'000) of all IPTs during the financial period under review	Aggregate value of all IPTs conducted during the financial year under review under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000)
 (1) Econ Healthcare Pte Ltd Lease of 3 nursing homes: (a) ECON Medicare Centre and Nursing Home – Braddell (b) ECON Medicare Centre and Nursing Home – Choa Chu Kang (c) ECON Medicare Centre and Nursing Home – Upper East Coast Rental deposit for 3 nursing homes: (d) ECON Medicare Centre and Nursing Home – Braddell (e) ECON Medicare Centre and Nursing Home – Choa Chu Kang (f) ECON Medicare Centre and Nursing Home – Upper East Coast 	2,315	Not applicable - the Group does not have a shareholders' mandate under Rule 920
 (2) Econ Medicare Centre Holdings Pte Ltd (a) Lease of ECON Medicare Centre and Nursing Home – Recreation Road (b) Lease of staff quarters at Recreation Road (c) Sublease agreement for Hexacube office (d) Accounting service agreement 	381	
(3) Econ Healthcare Pte Ltd(a) Sub lease agreement for Chai Chee Nursing Home	704	
 (4) Ekang International Holdings Pte. Ltd. (a) Lease of Hexacube office (b) Rental deposit top up for Hexacube office 	526	
(5) TMI Technologies Pte Ltd(a) Sub lease arrangement for Hexacube office(b) Accounting service agreement	12	

Other information required for Full Year Announcement

10 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company has procured undertakings from all its Directors and Executive Officers (in the format set out in Appendix 7H) under Rule 720(1) of the of the SGX-ST Listing Manual Section B: Rules of Catalist.

11 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with any director, CEO and/or substantial shareholder	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Koh Hin Ling	70	Wife of Ong Chu Poh (Executive Chairman and Group Chief Executive Officer); and Mother of Ong Hui Ming (Executive Director and Deputy Chief Executive Officer)	Director of TCM, TCM practitioner and Director of the Group's principal subsidiaries, with effect from 1994	N.A.

Other information required for Full Year Announcement

12 Use of IPO proceeds

Pursuant to the Company's initial public offering on 19 April 2021, the Company received gross proceeds of S\$14.0 million from the placement of new shares. As at the date of this announcement, the net proceeds have been utilised as follows:

		Amount utilised as	Balance at the
	Revised balance	at the date of this	date of this
	(as disclosed in	condensed	condensed
	announcement on	financial	financial
	8 June 2023) ⁽¹⁾	statements (2)	statements
	S\$'000	S\$'000	S\$'000
Expansion plans in Singapore as well as overseas through, among others, joint ventures, strategic collaborations, mergers and acquisitions, or investments; together with upgrading of existing medicare centres and nursing homes and other facilities,			
including equipment and IT infrastructure General corporate and working capital	7,947	7,385	562
purposes	2,070	_	2,070
Total	10,017	7,385	2,632

(1) As announced on 8 June 2023, the Company announced that net proceeds of S\$4.0 million had been utilised and that the use of proceeds would be revised to allocate the unutilised balance proceeds of S\$10.0 million to the consolidated use of expansion plans and upgrading plans of the Group for existing centres and facilities.

⁽²⁾ The amount utilised as at the date of this announcement refer to the expenses billed to date and amount paid up to date.

BY ORDER OF THE BOARD

Ong Chu Poh Executive Chairman and Group Chief Executive Officer 28 May 2024